Efficacy of lenvatinib versus sorafenib in the primary treatment of advanced hepatocellular carcinoma: A meta‐analysis

Abstract Background and Aim Molecular‐targeted agents such as lenvatinib and sorafenib have been approved to treat hepatocellular carcinoma (HCC). However, the choice between these two agents in the primary treatment for advanced HCC is still under debate with conflicting results. We sought to evalu...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Vikash Jaiswal, Maha Hameed, Sidra Naz, Poulami Roy, Novonil Deb, Janta Ukrani, Gautham Varun Krishna Mohan, Amira M Taha, Helen Huang, Vikash Kumar, Bhavyakumar Vachhani, Abdelrahman M Attia, Supti D Nath, Mostafa A Solimn, Dattatreya Mukherjee
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Wiley 2023-12-01
Edice:	JGH Open
Témata:	hepatocellular carcinoma lenvatinib mortality sorafenib
On-line přístup:	https://doi.org/10.1002/jgh3.12999
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!